Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01188694 · ClinicalTrials.gov registry record · Phase 2
Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01188694: Completed Phase 2 study, sponsored by University of Washington.
NCT01188694 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01188694, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
Posttraumatic stress disorder (PTSD) is a condition that involves intense memories of a traumatic event and intense, persistent feelings of anxiety. There are several effective therapies for PTSD, but they are often time consuming. The investigators want to see if the investigators can shorten treatment time while keeping therapy effective by adding a medication called methylene blue, USP, taken orally as a pill, to the therapy. The specific aims are: 1) To see whether medication plus psychotherapy improves PTSD symptoms more than placebo plus psychotherapy or a waitlist; 2) To examine the long-term outcome of those receiving medication plus psychotherapy 1 and 3 months after treatment has ended; 3) To examine whether medication plus psychotherapy helps with depression, trauma-related cognitions, and functioning.
Primary Outcome
PTSD Symptom Scale - Interview Version, higher scores represent higher PTSD severity (range 0 - 51)
Interventions
- DRUG Psychotherapy plus Methylene Blue, USP
- BEHAVIORAL Psychotherapy plus Placebo
- BEHAVIORAL Delayed Psychotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
What the finished NCT01188694 record still lists
NCT01188694 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 3 interventions - of which Psychotherapy plus Methylene Blue, USP is the first listed.
NCT01188694 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01188694 about?
NCT01188694 is a clinical study titled "Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)". Posttraumatic stress disorder (PTSD) is a condition that involves intense memories of a traumatic event and intense, persistent feelings of anxiety. There are several effective therapies for PTSD, but they are often time consuming. The investigators want to see if the investigators can shorten treat...
What is the current status of trial NCT01188694?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2009-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01188694?
The interventions under investigation include: Psychotherapy plus Methylene Blue, USP (DRUG), Psychotherapy plus Placebo (BEHAVIORAL), Delayed Psychotherapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT01188694?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01188694's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia